JP2012520852A5 - - Google Patents

Download PDF

Info

Publication number
JP2012520852A5
JP2012520852A5 JP2012500251A JP2012500251A JP2012520852A5 JP 2012520852 A5 JP2012520852 A5 JP 2012520852A5 JP 2012500251 A JP2012500251 A JP 2012500251A JP 2012500251 A JP2012500251 A JP 2012500251A JP 2012520852 A5 JP2012520852 A5 JP 2012520852A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
disease
antigenic composition
antigenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012500251A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012520852A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/053519 external-priority patent/WO2010106127A2/en
Publication of JP2012520852A publication Critical patent/JP2012520852A/ja
Publication of JP2012520852A5 publication Critical patent/JP2012520852A5/ja
Withdrawn legal-status Critical Current

Links

JP2012500251A 2009-03-18 2010-03-18 治療的使用のための方法 Withdrawn JP2012520852A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16116509P 2009-03-18 2009-03-18
US61/161,165 2009-03-18
US25602809P 2009-10-29 2009-10-29
US61/256,028 2009-10-29
PCT/EP2010/053519 WO2010106127A2 (en) 2009-03-18 2010-03-18 Method for therapeutic use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015134900A Division JP2015221809A (ja) 2009-03-18 2015-07-06 治療的使用のための方法

Publications (2)

Publication Number Publication Date
JP2012520852A JP2012520852A (ja) 2012-09-10
JP2012520852A5 true JP2012520852A5 (cg-RX-API-DMAC7.html) 2013-04-25

Family

ID=42376556

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012500251A Withdrawn JP2012520852A (ja) 2009-03-18 2010-03-18 治療的使用のための方法
JP2015134900A Pending JP2015221809A (ja) 2009-03-18 2015-07-06 治療的使用のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015134900A Pending JP2015221809A (ja) 2009-03-18 2015-07-06 治療的使用のための方法

Country Status (17)

Country Link
US (1) US20100285108A1 (cg-RX-API-DMAC7.html)
EP (2) EP3978517A1 (cg-RX-API-DMAC7.html)
JP (2) JP2012520852A (cg-RX-API-DMAC7.html)
KR (1) KR20120004994A (cg-RX-API-DMAC7.html)
CN (1) CN102428101B (cg-RX-API-DMAC7.html)
AU (1) AU2010224824B2 (cg-RX-API-DMAC7.html)
CA (1) CA2755683A1 (cg-RX-API-DMAC7.html)
DK (1) DK2408807T3 (cg-RX-API-DMAC7.html)
ES (1) ES2885398T3 (cg-RX-API-DMAC7.html)
HU (1) HUE055739T2 (cg-RX-API-DMAC7.html)
IL (1) IL214919A (cg-RX-API-DMAC7.html)
MX (1) MX2011009654A (cg-RX-API-DMAC7.html)
PT (1) PT2408807T (cg-RX-API-DMAC7.html)
RU (1) RU2579659C2 (cg-RX-API-DMAC7.html)
SG (1) SG174871A1 (cg-RX-API-DMAC7.html)
SI (1) SI2408807T1 (cg-RX-API-DMAC7.html)
WO (1) WO2010106127A2 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
EP4218794A3 (en) * 2009-06-10 2023-09-13 New York University Immunological targeting of pathological tau proteins
WO2012045882A2 (en) * 2010-10-07 2012-04-12 Ac Immune S.A. Pharmaceutical composition
AU2013205313B2 (en) * 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
CA2811188C (en) * 2011-09-23 2020-04-28 Andrea Pfeifer Vaccine therapy
JP6358953B2 (ja) 2011-10-07 2018-07-18 エーシー イミューン エス.エー. タウを認識するホスホ特異的抗体
CA2869438C (en) 2012-04-05 2021-08-17 Ac Immune S.A. Humanized tau antibody
EP2847322B1 (en) 2012-05-08 2019-06-26 Western University Of Health Sciences Standardized ex vivo platforms for the antigen-specific expansion of cd4+ t cell populations
MX374811B (es) 2013-03-15 2025-03-06 Ac Immune Sa Anticuerpos anti-tau y métodos de uso.
EP3166688B1 (en) 2014-07-08 2024-08-21 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
EP3261678B8 (en) * 2015-01-23 2021-03-17 Helix Biopharma Corp. Antibody-urease conjugates for therapeutic purposes
US10988528B2 (en) 2015-08-13 2021-04-27 New York University Antibody-based molecules specific for the truncated ASP421 epitope of Tau and their uses in the diagnosis and treatment of tauopathy
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
TW202333768A (zh) 2017-10-25 2023-09-01 美商健生醫藥公司 Tau胜肽之組成物及其用途
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
SG11202108312PA (en) 2019-02-08 2021-08-30 Ac Immune Sa Method of safe administration of phosphorylated tau peptide vaccine
MX2021012994A (es) * 2019-04-24 2022-03-04 Janssen Pharmaceuticals Inc Administracion heterologa de vacunas tau.
CN113853214A (zh) * 2019-05-21 2021-12-28 Ac免疫有限公司 抗Aβ疫苗治疗
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
KR20250135293A (ko) 2023-01-26 2025-09-12 에이씨 이뮨 에스에이 리포좀 구조체

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7408027B1 (en) * 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
AU690092B2 (en) * 1992-12-14 1998-04-23 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
WO1997034145A1 (fr) * 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
WO1998022120A1 (en) * 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
AU2001273361A1 (en) * 2000-07-11 2002-01-21 Molecular Geriatrics Corporation Reagents and methods for identification of binding agents
KR20050101537A (ko) 2002-12-24 2005-10-24 뉴로켐 (인터내셔널) 리미티드 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제
US8663650B2 (en) * 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
EP1494000A1 (en) * 2003-07-02 2005-01-05 Sicpa Holding S.A. Method of marking a material with ions already comprised in said material and method of verifying the authenticity of said material
US20050261475A1 (en) * 2004-02-13 2005-11-24 Harvard Medical School Solid-phase capture-release-tag methods for phosphoproteomic analyses
KR101277004B1 (ko) * 2004-02-20 2013-06-24 에이씨 이뮨 에스.에이. 초분자 구조체를 포함하는 방법 및 조성물
CA2633399C (en) * 2005-12-12 2016-01-26 Ac Immune S.A. Therapeutic vaccine
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20080220449A1 (en) * 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція

Similar Documents

Publication Publication Date Title
JP2021501147A5 (cg-RX-API-DMAC7.html)
JP2015221809A5 (cg-RX-API-DMAC7.html)
RU2011141889A (ru) Способ для применения в терапии
Schneeberger et al. Vaccination for Parkinson's disease
JP6029280B2 (ja) D−ペプチドを有する抗−アミロイドβ−ペプチド抗体を製造するための組成物
JP2012530055A5 (cg-RX-API-DMAC7.html)
US11684576B2 (en) Method of safe administration of phosphorylated tau peptide vaccine
CN111787942A (zh) 磷酸化Tau肽的组合物及其用途
JP2022529529A5 (cg-RX-API-DMAC7.html)
JP2017531613A5 (cg-RX-API-DMAC7.html)
JP2009519915A5 (cg-RX-API-DMAC7.html)
JP2017521064A5 (cg-RX-API-DMAC7.html)
JP2010516290A5 (cg-RX-API-DMAC7.html)
JP2014531455A5 (cg-RX-API-DMAC7.html)
MY183989A (en) Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
JP2008506665A5 (cg-RX-API-DMAC7.html)
JP5474807B2 (ja) 改変アミロイドβペプチド
JP2017537926A5 (cg-RX-API-DMAC7.html)
CN114173812A (zh) Tau疫苗的异源给予
Davtyan et al. Immunogenicity of DNA-and recombinant protein-based Alzheimer disease epitope vaccines
JP2016526044A5 (cg-RX-API-DMAC7.html)
JP2019530441A5 (cg-RX-API-DMAC7.html)
EP2300494A1 (en) Anti-amyloid immunogenic compositions, methods and uses
CA3095983A1 (en) Anti-abeta therapeutic vaccines
JP2016516054A5 (cg-RX-API-DMAC7.html)